Determining whether an asymptomatic individual with Prostate-Specific Antigen (PSA) levels below 20 ng ml−1 has prostate cancer in the absence of definitive, biopsy-based evidence continues to present a significant challenge to clinicians who must decide whether such individuals with low PSA values have prostate cancer. The gene discussed is KLK3; the disease is prostate carcinoma.